603676.SH
Xizang Weixinkang Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.41
+0.36%Oct 29, 2026, 08:16 UTC
Weixinkang reported first-nine-months 2026 revenue of 817 million yuan, down 5.31% year over year, net profit attributable to shareholders of 177 million yuan, down 19.45%, and adjusted net profit of 137 million yuan, down 19.16%.
Source:Oct 29, 2026, 08:16 UTC
Weixinkang reported third-quarter 2026 revenue of 232 million yuan, down 15.90% year over year, and net profit attributable to shareholders of 33.623 million yuan, down 7.60%.
Source:Sep 10, 2026, 07:37 UTC
Weixinkang's wholly owned subsidiary Inner Mongolia Baiyi Pharmaceutical received a drug registration certificate from the National Medical Products Administration for water-soluble vitamins for injection, deemed equivalent to passing consistency evaluation.
Source:Aug 31, 2026, 08:42 UTC
Weixin Kang's wholly-owned subsidiary Yangpu Jingtai Pharmaceutical received approval from China's National Medical Products Administration for a supplementary application for Potassium Aspartate Injection, adding a new specification and deemed to pass consistency evaluation.
Source:Aug 27, 2026, 09:08 UTC
Weixinkang announced its 2026 first-half results: net profit attributable to shareholders was 143 million yuan, down 21.81% year-on-year.
Source: